Another Year Of Close Collaboration Authorized In Australia
ACCC Extends Permission For GBMA And Medicines Australia To Share Information
Executive Summary
Australian off-patent industry association the GBMA and brand body Medicines Australia can continue to collaborate closely as part of work to mitigate shortages in the context of the COVID-19 pandemic, the ACCC has decided, extending an existing authorization by a further year.
You may also be interested in...
Australian Industry Working To Minimize Medicines Shortages
Australia’s branded and generic drug industry associations have jointly raised concerns about the impact ongoing shortages could have on the country’s supply of medicines.
Covid-19: Australian Competition Body Confirms Industry Collaboration Conditions
A collaboration between the Australian Generic and Biosimilar Medicines Association and brand industry body Medicines Australia against the backdrop of COVID-19 has been endorsed through a final determination from the country’s competition body that clarifies the conditions of the ongoing arrangement.
Australian Body Confirms Collaboration Conditions
A collaboration between the Australian Generic and Biosimilar Medicines Association and brand industry body Medicines Australia against the backdrop of COVID-19 has been endorsed through a final determination from the country’s competition body that clarifies the conditions of the ongoing arrangement.